Nevertheless, this study demonstrated that IRS-H versus -L status robustly stratified anti-PD-(L)1 monotherapy benefit (by both rwPFS and OS) across tumor types, IRS status was predictive in those treated with anti-PD-(L)1 in the >first line, and IRS added benefit beyond MSI/TMB status alone. Here, IARS1 is linked to neoplasm.